Physiologically Relevant Tumor Modeling for Oncology Research
Orthotopic Mouse Models
Why Medicilon’s Orthotopic Models Stand Out
Understanding how tumors behave in their natural environment is critical for effective drug development. Medicilon’s Orthotopic Mouse Models provide a highly relevant preclinical platform by implanting tumor cells directly into their tissue of origin. This approach ensures realistic tumor growth, mimics human cancer progression, and enhances drug response predictability.
Tumors Grow in the Specific Site
Cancer cells are implanted into their natural organ sites, preserving critical tumor-tissue interactions.
Better Metastasis Simulation
These models replicate cancer invasion and spread, making them ideal for metastasis studies.
Realistic Drug Response Data
By growing in a physiologically accurate environment, tumors react to treatments more like they would in human patients.
Advanced Imaging Capabilities
Use of luciferase-labeled cell lines enable real-time monitoring of tumor progression.
Customized for Your Research
We develop tailored models to match your specific oncology research needs.
Expansive Orthotopic Model Portfolio
Medicilon offers a diverse selection of orthotopic models Many of these models include luciferase-labeled cell lines, allowing for tracking live tumors.
Our Available Orthotopic Models:
Cancer Type
Orthotopic Model
Luciferase Cell Line
- Bladder Cancer
MB49-luc
- Brain Cancer
U87-MG-luc, U251-luc, G261-luc
- Breast cancer
MDA-MB-231-luc, MCF-7-luc, 4T1-luc
- Fibrosarcoma
HT1080-luc
- Gastric cancer
- Liver
HuH-7-luc, Hep G2-luc, H22-luc
- Lung cancer
A549-luc, NCI-H1975-luc, NCI-H1650, LLC1-luc
- Melanoma
B16-F10-luc
- Osteosarcoma
- Ovarian cancer
SK-OV-3-luc
- Pancreas cancer
Mia-Paca 2-luc, PANC-1-luc, Panc 02-luc
- Prostate Cancer
PC-3-luc
- Renal Cancer
A498-luc
- Leukemia
K562-luc, MV-4-11-luc, THP-1-luc
- Lymphoma
Raji-luc, Nalm-6-luc, JeKo-1-luc
- Myeloma
NCI-H292-luc, MM.1S-luc, OPM-luc
How Orthotopic Models Power Cancer Research
- Testing Drug Efficacy in a Natural Tumor Environment: Get accurate data on tumor growth inhibition, drug penetration, and therapeutic impact.
- Metastasis Research: Study how cancer spreads, test anti-metastatic therapies, and track tumor dissemination in real-time.
- Combination Therapy Development: Evaluate the effectiveness of multi-drug regimens and optimize treatment strategies.
- Immune System & Tumor Microenvironment Studies: Explore how tumors interact with immune cells, aiding in the development of immunotherapies.
How Orthotopic Models Power Cancer Research
Key Models highlights
- Testing Drug Efficacy in a Natural Tumor Environment: Get accurate data on tumor growth inhibition, drug penetration, and therapeutic impact.
- Metastasis Research: Study how cancer spreads, test anti-metastatic therapies, and track tumor dissemination in real-time.
- Combination Therapy Development: Evaluate the effectiveness of multi-drug regimens and optimize treatment strategies.
- Immune System & Tumor Microenvironment Studies: Explore how tumors interact with immune cells, aiding in the development of immunotherapies.
Tumor
Neurological disease
Digestive system disease
Metabolic disease
Cardiovascular diseases
Inflammatory & immune disease
Other disease models
A Smarter, Integrated Approach to Drug Screening
Medicilon’s orthotopic models aren’t just standalone tools – they integrate seamlessly with other preclinical drug screening platforms.
By using the same tumor models across different platforms, Medicilon ensures consistent, high-quality data, improving drug translation success rates.
- In Vitro Cell-Based Screening – Identify potential drug candidates using the corresponding cancer cell lines.
- Ex Vivo Tumor Cultures – Study tumor-immune system interactions in controlled lab environments.
- In Vivo Orthotopic Models – Validate drugs in a fully functional tumor system for real-world applicability.
Tumor Models
Non-tumor Models
cancer therapy INNOVATION
Beyond Orthotopic Models, A Full-Spectrum Oncology Research Suite
Tumor models:
Medicilon provides a comprehensive range of oncology models, including:
- CDX Models – Fast, reliable tumor models for early-phase drug screening.
- PDX Models – Clinically relevant models for personalized medicine research.
- Syngeneic Mouse Models – Immunocompetent tumor models for evaluating novel cancer therapies in a controlled setting.
This holistic approach ensures that researchers can seamlessly transition from early drug discovery to translational research, accelerating the path to clinical trials.
